# Asthma: Making New Discoveries into Better Therapies

> **NIH NIH R13** · KEYSTONE SYMPOSIA · 2020 · $13,200

## Abstract

ABSTRACT
Support is requested for a Keystone Symposia conference entitled Asthma: Making New Discoveries into
Better Therapies organized by Drs. Michael J. Holtzman, Philippa C. Marrack, Anne I. Sperling and Prescott G.
Woodruff. The conference will be held in Snowbird, Utah from April 2-6, 2020.
Asthma and related diseases in the form of COPD and asthma-COPD are a remarkably common, affecting
over 50 million patients in the US alone. Asthma is typically thought to arise from an aberrant type 2 immune
response, but the cellular and molecular mechanisms that lead to asthma require more precise definition. In
particular, a subset of patients have asthma that is associated with or exacerbated by aberrant non-type 2
immune mechanisms which are inadequately characterized. These patients respond poorly to currently
available therapies and represent a significant unmet clinical need. Recent clinical trials of anti-asthma
therapeutics have revealed both successes and also some unforeseen failures; thus, convening a high-level
scientific conference that broadly addresses the state of the field is particularly timely and important. The
2020 Keystone Symposia conference on asthma will highlight the most recent basic science breakthroughs in
the pathogenesis of asthma and related inflammatory airway diseases and focus on the development of new
therapeutics for asthma, as well as related chronic lower respiratory disease, which is now the third most
common cause of death in the U.S and the fifth most common worldwide. In addition, sessions of the program
will review these discoveries in the context of new therapeutics and therapeutic directions, including precision
medicine. The program has been designed to emphasize the immunological and interrelated non-
immunological approaches to identify, validate, and translate new biological targets into new therapeutics. The
topic is timely and urgent given the recent mechanistic insights into inflammatory airway disease and the
current maturation of new biological therapies for asthma that are now just entering clinical application.

## Key facts

- **NIH application ID:** 9988669
- **Project number:** 1R13HL152474-01
- **Recipient organization:** KEYSTONE SYMPOSIA
- **Principal Investigator:** Thale Cross Jarvis
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $13,200
- **Award type:** 1
- **Project period:** 2020-08-02 → 2021-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9988669

## Citation

> US National Institutes of Health, RePORTER application 9988669, Asthma: Making New Discoveries into Better Therapies (1R13HL152474-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/9988669. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*